Ayala Pharmaceuticals, Inc. Common Stock
AYLA
AYLA was delisted on the 18th of January, 2023.
15 hedge funds and large institutions have $4.57M invested in Ayala Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 14 → 15 (+1)
76% less capital invested
Capital invested by funds: $18.8M → $4.57M (-$14.3M)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$930K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$310K |
| 3 |
Renaissance Technologies
New York
|
+$87K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$72.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.58M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$995K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$248K |
| 4 |
SCM
Sio Capital Management
New York
|
-$240K |
| 5 |
Millennium Management
New York
|
-$95.8K |
AYLA Hedge Fund Activity: Q2 2022 in Review
15 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q2 2022, worth a combined $4.57M — down 76% from $18.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AYLA positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 6 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $930K. The largest seller was Wellington Management Group, exiting entirely with an estimated $2.58M sold.
- 15 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q2 2022, up from 14 in Q1 2022.
- Funds reported $4.57M of Ayala Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 76% quarter-over-quarter.
- 5 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of +1 holder.
- The largest Ayala Pharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Citigroup, an estimated $930K added.
- The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Wellington Management Group, an estimated $2.58M sold.
Based on aggregated 13F filings for Q2 2022.